



Organisation of Pharmaceutical Producers of India



Map not to scale

Global Capabilities Centres

Enabling an environment for
Innovation and Excellence - Bharat Ke Liye



Expertise and innovation to power GCCs

Reimagine your GCC for a modern, digital-first world with a trusted partner



Scale up faster with ready-to-deploy healthcare expertise



Grow non-linearly with life sciences- contextualized technology



Accelerate innovation with Generative AI-powered platforms



Embed agility from day one with flexible engagement models



Support markets around the world with a global partner



Stay future-ready with an industry-leading practitioner perspective



FOREWORD

Anil Matai

Director General, OPPI

The evolution of India's pharmaceutical industry today transcends traditional boundaries. From being celebrated as the 'pharmacy of the world' for its production and distribution of generic medicines, India now stands at the forefront of innovation and digital transformation within the pharmaceutical landscape.

This report sheds light on a remarkable paradigm shift within the industry, as India emerges not only as a manufacturing powerhouse but also as a nucleus of pharmaceutical innovation. Through establishment of new captives of Global Capability Centres (GCCs) by renowned multinational corporations, alongside substantial expansions of existing ones, India is now a pivotal hub for critical functions ranging from clinical trials to drug discovery. What sets India apart in this new narrative is its unwavering commitment to embracing cutting-edge technologies such as Gen AI, AR/VR, and IoT, thereby redefining the contours of pharmaceutical research and development.

Positioned at the confluence of global expertise and local talent, GCCs in India have also played a pivotal role in generating job opportunities for the community, upskilling of the workforce as well as increasing the knowledge base of the country - 38 pharma GCCs in India employ over 75,000 top notch talented people. The success stories of various GCCs highlighted in this report, exemplify the collaborative efforts, underscoring a profound synergy aimed at catalyzing future growth and driving forward groundbreaking pharmaceutical research.

As the voice of research-based global pharmaceutical companies in India, we at OPPI, the Organisation of Pharmaceutical Producers of India, have always been an integral part of the country's healthcare journey. Since our inception in 1965, we have remained committed to supporting the nation's healthcare objectives, putting patients at the core of all decision making and collaborating with all stakeholders to find sustainable solutions to realize the collective vision of *Health for All*.

Our initiative, *Bharat Ke Liye*, encapsulates the essence of this commitment and the determination to fulfill our honourable Prime Minister's mission to make India the vanguard of global pharmaceutical innovation. In this report, we bring you 13 of our member-companies fuelled with achieving the same goal.

INDEX



pg. 06

Unlocking the power of science to transform healthcare



pg. 10

Tapping India's talent pool to offer better healthcare solutions worldwide



pg. 12

Transforming patients' lives with science



pg. 14

Caring and creating for the community



pg. 16

Making a difference – from local to global



pg. 18

Getting ahead of disease together



pg. 20

United As One for Patients to help create, improve and prolong lives



pg. 22

Leveraging break-through science to better lives.



pg. 25

Developing in India for the world



pg. 28

A Century of Innovation...



pg. 30

Promoting Innovation; Perfecting Healthcare



pg. 33

A healthier future. It's what drives us to innovate



pg. 39

Innovation and expertise. From India to the world!



Unlocking the power of science to transform healthcare

Innovations that Impact Lives.

AstraZeneca, a science-led, patient-focused global pharmaceutical company is committed to transform healthcare for billions of people by leveraging on science and innovation to deliver new medicines that address unmet medical needs. The company strives for excellence in research, development and commercialisation of prescription medicines that aim to transform the lives of patients with improved outcomes and a better quality of life.

AstraZeneca is using distinctive scientific capabilities, delivering a pipeline of life changing medicines, working towards effective treatment and prevention and, ultimately committed to finding a cure for some of the world's most complex diseases.



GCC:
Bengaluru, Chennai



No. of Employees:
~3100

The company has a wide range of innovative medicines across multiple therapy areas, including oncology, biopharmaceuticals and rare diseases, and works diligently to improve access to them, such that no patient is left behind.

R&D that delivers the quickest and greatest impact possible.

AstraZeneca is relentlessly working to improve their understanding of disease and discover new ways to affect disease drivers. A third of its pipeline is focused on new drug modalities, taking science further to create the next generation of medicines. Through R&D the organisation is improving the ways they predict clinical success so as to accelerate delivery of the right medicines to the right patients every time.

Pioneering new approaches in the clinic, the company uses AI to help deduce the best molecules to make in the shortest time, across 70% of their small molecule chemistry projects. AI-powered image analysis and advanced imaging tools aid in analysing the heterogeneity of the patient population and develop potential medicines faster. Data science experts are building machine learning algorithms to combine diverse data sets such as clinical trial data and real-world

“The ratio of insourcing to outsourcing of IT and tech has definitely moved - from 80% of outsourcing earlier, we are now doing 70% of work inhouse.”

Siva Padmanabhan
MD and Head, Global Innovation & Technology Centre, AstraZeneca

data, to identify patterns in disease progression or in how patients respond to different therapies.

The R&D team is responsible for the regulatory responses to assessment reports and health authority queries to uphold competitive label. The team also takes care of post-marketing safety surveillance and signal management, safety reporting, license renewals and annual reports, variations, patient risk management strategies and PASS & ESR studies supporting 50+ brands of AstraZeneca. Over the years, the site has expanded with additional functions setting up their teams viz. Clinical Data & Insights and Clinical and Regulatory Writing.

The Global Capability Center (GCC) in India, is currently home to over 3100 employees, spread across IT services, Global Business Services (GBS) and R&D Services and has grown in strength since its inception

in 2014. The Global Innovation & Technology Centre (GITC) Chennai and R&D Bengaluru sites together play a key role in innovation and transformation programs, enabling and empowering AstraZeneca's core business processes – from discovery, development, production, launches to supply, all the way through the value chain. Originally started as an IT Support Centre, over the years the GITC has built leading-edge technology capabilities. Today, GITC is a key engine for AstraZeneca's digital journey and a major source of Technology Innovation, with over 50% of global IT staff located here. Some of the largest IT programs are delivered end-to-end from the GITC and many strategic, future IT platforms and capabilities are being scaled from here. The GITC provides a broad range of capabilities & services including Software Engineering, Cybersecurity, IT Infrastructure management, Cloud, Hyper Automation, Artificial Intelligence (AI) and Machine Learning (ML), eXtended Reality and Internet of Things. The Centre continues to invest in building futuristic technology capabilities and is focused on driving

GITC Chennai



Technology Innovation for the organization globally.

GBS identifies, builds, and delivers excellent shared services across the company with innovation, expertise, and scale operating across Chennai and Bengaluru. GBS supports Global Analytics (GA), Global Assurance and Reporting (GARS), Global Commercial Operations (GCO), Global Data Office (GDO) to name a few. Established in 2017, the GBS India team has 450+ team members, helping internal stakeholders free up time and resources and providing a path to new capabilities.

Today, India houses over 1500 GCCs, with over 1.5 million professionals engaged across skillsets. These centres are playing strategic roles given the talent, resilience, and innovation that India is able to deliver across every industry. AstraZeneca proudly contributes to the organisations' digital agenda, underpinned by its relentless focus on delivering medicines to maximum patients.

To bring the best talent to bear on the toughest problems, AstraZeneca

collaborates with others regularly. Globally this has led to more than 2,000 active collaborations across academia, biotech, and industry. Since 2012, the company has championed a uniquely open approach to working with academia and non-governmental organisations, completely shifting the nature of private-public collaborations. The company's scientists work with others in dedicated laboratories in universities and research institutions aiming to generate high impact science to support possible future advances in life-changing medicines.

Working inclusively and collaboratively with others, they are supporting new talent and ideas. What's more, all these processes are done sustainably, aimed at rapidly making the company carbon negative. Indeed, AstraZeneca is making healthcare systems more reliable and resilient, ensuring better outcomes for patients and helping increase access to healthcare locally and globally. For, as pioneers in science, they are united in the aim of improving the lives of patients in India and around the world.



R&D Bengaluru





Tapping India's talent pool to offer better healthcare solutions worldwide

A legacy of contributing to healthcare.

Bayer has been operating in India for over 125 years, making significant contributions towards advancing healthcare in India while promoting inclusive and sustainable growth through innovation. The company is committed to providing innovative medicines to meet the country's unmet health needs and improve patients' quality of life, proudly 'Making in India for India and the World'.

Investigations & innovations: Data Science and Analytics Center

Bayer's Center of Excellence for Pharmaceuticals in Hyderabad caters to the growing global demand for Data Sciences and Analysis (DS&A) enabling Bayer Pharmaceuticals to focus not only on excellence in the

execution of clinical trial deliverables but also to contribute to industry-leading solutions in analytical trends and methodologies. As a support to research and development efforts, currently, Phase III & IV clinical trial participation in India is undertaken here with an aim to accelerate bringing products in the areas of oncology and cardiology to the country. Additionally, India is also contributing to AI/ML projects for Bayer's global R&D.

The Hyderabad centre has been selected as a key APAC hub, as India has a significant talent pool to support global drug discovery and manufacturing initiatives. There are over 100 employees currently working here, supporting R&D operations. Plans to expand the workforce in the future are underway, enabling meaningful job opportunities in the country.

Powering Performance: Global Business Services

Bayer has a centre in Bengaluru which is part of the Global Shared Service Centre Delivery Network. With the purpose of powering their business to enable 'Health for all, Hunger for none', GBS India's team of 850+ diligently delivers as per the GBS strategy. The centre provides support for finance accounting,

procurement, invoice processing & payments, cash applications, global transformation & project management for Bayer across countries in North America, South America, Europe, Africa & APAC and in multiple languages. The site, operational since 2005, delivers on business processes in an efficient and effective manner, thereby generating business value through operational excellence.

Solutions on Course: Clinical Trials Operations

In India, Bayer Pharma is advancing around 17 projects in ongoing Phase II, III and IV clinical trials across a range of potential therapeutic modalities and indications, with a focus on oncology, cardiovascular, diabetes, ophthalmology and women's health. Additionally, Indian patients are also being included in global clinical trials to ensure this demographic is being studied. This is key to ensure that as soon as approvals for these medications are in place, these medications can be introduced to the Indian market.

Absolutely Atmanirbhar: Manufacturing Abilities

More than 60% of the products across healthcare (including the pharmaceutical and consumer health

portfolio) are manufactured in India, with 100% of Bayer Consumer Health products being locally manufactured. Bayer has deep-rooted local manufacturing partnerships to encourage local production and entrepreneurship in line with the government's Make in India plan.

Several materials are also sourced from India which are being utilized at manufacturing units in Europe, Latin America, and elsewhere. In addition to contract manufacturing, Bayer is also engaged in strategic 'Loan and License Manufacturing' partnerships.

Strength & Service: Partnerships and collaborations

Bayer and the National Cancer Institute of India-All India Institute of Medical Sciences (NCI-AIIMS)- The collaboration, initiated in 2021, brought cancer screening to patients at high risk of cancer in underserved rural communities in India, with an aim to help reduce disparities in access to cancer care.

Bayer and the International Society of Nephrology (ISN)

Bayer has collaborated with ISN to design and execute a unique program for primary care physicians to raise awareness on kidney disease. The program known as Nephrology for Non-Nephrologists, has benefited ~200 physicians. This is a 6-month long program with offline and online phase educating physicians on kidney disease. HCPs post completion of all the modules are certified by the International Society of Nephrology. The collaboration has also setup the yearly Bayer-ISN Pioneer Awards in 2022, to promote research, innovation and recognize HCPs for their special contribution in the field of Nephrology. To drive awareness around Chronic Kidney disease (CKD) in patients with Type 2 diabetes, Bayer with ISN launched a campaign titled #ReadyToSlowDown.

Preserve the Uterus


A nationwide campaign was implemented in partnership with the Federation of

Obstetric and Gynaecological Societies of India (FOGSI) to raise awareness among women and educate health care practitioners about the vital reproductive organ and the diseases that impact it with a view to avoiding an untimely or unjustified hysterectomy.


The United Nations Population Fund (UNFPA) and Bayer Global Sustainability are working on a partnership to build innovative models of care delivery for family planning services focused on adolescent and teenage pregnancy. The partnership involves co-financing this innovative model. This project shall be piloted in Rajasthan and Chhattisgarh.

At Bayer, the aim is to help meet the contraceptive needs of 100 million women by 2030 in low to middle-income countries. The work in India is also crucial; the number projected for 2030 in terms of contribution to India is 5 million. With this goal in focus, Bayer has also contributed a grant of 200000 Euros to execute this in India in collaboration with the Family Planning Association of India (FPAI).

Bayer Thane Office



Physician conducting a clinical trial



GCC: Hyderabad



No. of Employees:
>100



Transforming patients' lives with science



New Innovation Hub in Hyderabad



No. of Employees: >1500



Investment: \$100mn

Bristol Myers Squibb (BMS), one of the world's largest biopharmaceutical companies, believes in the power of science to address some of the most challenging diseases of our time. The company's focus on these unmet needs comes during a remarkable time, when unprecedented scientific breakthroughs are advancing the treatment of disease as never before in human history.

Teams at Bristol Myers Squibb work every day to transform patients' lives through science. Each day, employees around the world work together for patients – they are at the center of everything the company does. The company

combines the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.

Bristol Myers Squibb announced the opening of a new facility in Hyderabad in February 2024. The state-of-the-art site will expand the company's global drug development and IT and digital capabilities and is expected to be home to over 1,500 employees.

The new site expands Bristol Myers Squibb's global footprint and will serve as



Inauguration of new Bristol Myers Squibb site in Hyderabad by the Honorable Minister for Industries & Information Technology of Telangana, Mr. D. Sridhar Babu and Christopher Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb

an innovation hub, as the company write the next chapter in their history. The company has invested over \$100 million in the creation of this cutting-edge facility.

The innovation hub in Hyderabad will accelerate drug development and enhance Bristol Myers Squibb's digital capabilities. It will help the

company further diversify their global workforce by adding world-class local talent and strengthening the ability to positively impact patients everywhere. The diverse talent pool ranging from specialization in information technology, medical writing, regulatory process and statistical programmers, operations besides physicians, will help

global drug development process as well as IT processes.

BMS Hyderabad is an integrated global hub, focused on helping patients prevail over serious diseases by building sustainable and innovative solutions developing a diverse talent pool and expanding global reach.



The newly inaugurated Bristol Myers Squibb office in Hyderabad



Biocon Bristol Myers Squibb Research & Development Center (BBRC)



No. of Employees: ~1000

Biocon Bristol Myers Squibb Research & Development Center (BBRC)

Bristol Myers Squibb has an extensive R&D center in Bengaluru. Called 'The Biocon Bristol Myers Squibb

Research & Development Center (BBRC)' it is a collaboration between Bristol Myers Squibb and Syngene International, a Biocon-group company. Fully operational since 2009, the site is involved in Target Identification,

Lead Discovery, and Lead Optimization all the way through to early-stage Pharmaceutical Development and Clinical Biomarkers R&D. Close to 1000 people are involved in different activities in the R&D center.



Biocon Bristol Myers Squibb Research & Development Center (BBRC) site in Bengaluru



Caring and creating for the community

Helping people live longer, healthier, and more active lives.

Since its inception in India in 1993, Lilly has striven to offer superior pharmaceutical products that treat diabetes, gastric cancer, lung cancer, breast cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency.

Little over a decade later, the company knew it could do much more to accelerate the pace of its innovation. And thus, was born the Lilly Capability Center India, in 2016, with the aim of capitalizing on India's unique drug development capabilities. The LCCI was set up in Bengaluru, strategically chosen due to its concentration of R&D, electronics and software production companies.



Lilly Capability Center India (LCCI), Bengaluru



No. of Employees: ~3000

- LRL (Lilly Research Laboratories) functions at LCCI provide scientific, regulatory, safety, and quality support and services to enable the research and development process and ensure the quality and value of Lilly's products.
- Commercial functions at LCCI provide market research, marketing content, analytics, operational support, learning services and digital solutions to optimize the customer engagement and performance of Lilly's products.
- Tech@Lilly functions at LCCI provide cloud, automation, advanced analytics, data science, artificial intelligence, software product engineering and information security solutions and services to support the digital transformation and innovation of Lilly's business units and functions.

The convergence of knowledge to create better outcomes.

The story of the Lilly Capability Center India (LCCI) is one of rapid growth, innovation, and collaboration. Today, barely eight years later, this hub is a 3000-strong organization and is a vital part of Lilly's global operations, providing support and solutions for various functions,

such as clinical trials, technology, commercial, and core services.

LCCI operates through the convergence of different functions under Lilly Research Laboratories (LRL), Commercial, Tech@Lilly, and others. It plays a pivotal role in accelerating the development and delivery of innovative medicines to patients, by collaborating with Lilly teams across geographies and functions. It has also demonstrated its ability to leverage India's unique strengths in combining tech and biotech, creating cutting-edge tools and methods that accelerate the discovery and development of new medicines for patients around the world.

By leveraging its expertise in data analytics, artificial intelligence, and digital technologies, it enhances and optimizes Lilly's clinical trial processes and outcomes. A large and diverse tech group supports and develops the company's global technology stack. LCCI also drives innovation and experimentation in areas such as AI and machine learning, applying them to various biopharmaceutical challenges and opportunities.

Simultaneously, the commercial services team supports Lilly's global marketing strategy and execution, creating and delivering engaging, relevant content and campaigns for

different audiences and channels. Further, it also helps leverage the latest digital tools and platforms to enhance customer experience and satisfaction. Lastly, the hub also houses professionals that manage finance, human resources, and procurement, thereby streamlining and standardizing operations, reducing costs, and improving efficiency and quality.

A workplace ethic that's more inclusive, is more productive.

Echoing Lilly's commitment to diversity, inclusion, and excellence, the LCCI, too, ensures it follows the same principles. The centre has remained true to its parent company's philosophy, with a workforce that consists of 40% women, 21% employees from Indian campuses, and experienced hires that span 100+

companies across diverse industries. LCCI has been consistently recognized as a Great Place to Work, Happiest Workplace, and Best Workplace for Women. Their unwavering commitment to fostering a supportive environment is underscored by the periodic awards from the India Workplace Equity Index (IWEI) – Bronze and Silver – for exceptional efforts in Diversity, Equity, and Inclusion (DEI).



FERRING

PHARMACEUTICALS

Making a difference – from local to global

Using innovation to reduce inequalities!

Founded in the 1950s, Ferring soon rose to become a market leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Among recent notable achievements, is the company being included in Fortune's 2023 "Change the World" list – a salute to Ferring's #ProjectFamily Safe Birth Commitment, which aims to reduce maternal mortality in low and lower-middle income countries. In India since 1997, the company established an R&D site in Hyderabad some years ago, that has the distinction of being one among their 10 Global R&D sites, developing and

delivering life-changing treatments that benefit many.

FHPDC - Ferring India R&D Centre of Excellence

Ferring Hyderabad Product Development Centre (FHPDC) is one among Ferring's 10 global R&D sites. It was established in 2007 at Mumbai and later shifted to Hyderabad in 2020. FHPDC is located at Genome Valley, Hyderabad and spread over an area of ~20,000 square feet. FHPDC has been working on the concept of "local to local" and "local to global" product development, focusing on Ferring's Key Therapy Areas; "Reproductive Medicine & Maternal Health", Uro-Oncology and Gastroenterology.

Ferring India R&D is actively engaged on technology platforms like FDG's, SmaRTgel and LBOL-IR/XR. Over the years, the company has invested more than 60 million euros on R&D activities in India with a yearly investment of 1 - 2 million euros on capital expenditure.

The centre has capabilities for:

- End to End Pharmaceutical Product Development
- Innovative Packaging Solutions

- Clinical and Non-Clinical Development
- Regulatory Submission

A strong Scientific Team brings results

The team at FHPDC consists of around 40 scientists with masters degrees and Ph.D qualifications. The team has an average pharmaceutical development experience of more than 15 years.

Two products based on patent protected FDG technology platform have been approved by Indian Health Authorities and are ready for launch in India in 2023. Several other products in the therapy area of reproductive medicine and maternal health, uro-oncology and gastroenterology are in the late-stage development and will soon move to commercialization.



GCC:
Ferring Hyderabad
Product Development
Centre (FHPDC)



Investment:
60mn euros

Ferring Hyderabad Analytical lab



Ferring Hyderabad R&D building





Getting ahead of disease together

About GSK

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. The company aims to positively impact the health of over 2.5 billion people in the next 10 years with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.

GSK prioritizes innovation in vaccines and specialty medicines to prevent and treat disease. GSK focuses on science of the immune system and advanced technologies, investing in 4 core therapeutic areas (Infectious Diseases, HIV, Respiratory/Immunology and Oncology) to impact health at scale.

GSK is currently operating in over 75 countries and in India, the company has a legacy of 100 years.



GCC: Bengaluru



No. of Employees:
>2500

Global Capability Centre (GCC)

GSK Global Capability Centre (GCC), India was established at Bengaluru in 2021. This LEED Platinum certified smart working office is a strategic arm of GSK that was set up to house diverse talent to build differentiated capabilities for future global impact. GCC currently hosts over 2500 employees who are part of various global business operations with capabilities to support long-term success of Global Functions and Pharma R&D. The center is home to multiple teams of talented people across

- R&D
- Digital & Technology
- People Services
- Finance
- Procurement
- Legal Contracting Network (LCN)
- Transformation

The presence and co-location of these diverse teams fosters great collaboration which is key to the success of GSK GCC in India.

The R&D team at GCC

Part of the global network, the R&D team in GSK Global Capability Center, Bengaluru, also has satellite teams in Hyderabad and Mumbai. The team has been in India for the last 28 years.

The team is laser-focused on three priorities: Execution, Technology and Culture to competitively deliver on the much-needed transformational vaccines and medicines to patients around the world, who count on GSK, every day.

Over 1400 employees are working in R&D in India across key functions including Safety Science, Regulatory, Biostatistics, Clinical operations, Project Portfolio management, Publications, Clinical Trial Transparency and more.

The GCC R&D capabilities

Here is an overview of the different functions in R&D that highlights the importance of each team's role in contributing to drug development.

Clinical Operations: Activities across the value chain including critical R&D activities such as Data Management, Medical Writing, Study Delivery of Assets, system validation, quality control framework and Laboratory Management support within the Clinical Operations area are carried out by the teams at the Bengaluru center.

Biostatistics team is involved in drug development across all phases and providing data-driven insights,

including evidence generation from Real World Data, that ensures robust risk management and quality. Statisticians and programmers within the Biostatistics area essay key roles in regulatory submissions, publications, and development of innovative statistical methodologies.


The regulatory affairs group brings together the operation and execution aspects for key regulatory deliverables for both established products and new products, with activities that include compiling submission dossiers, Clinical Trial applications, Labeling Outputs, License Maintenance and Lifecycle Management (e.g., Renewals, Variations) and Regulatory Information Management.

The Global Safety group is involved in Triage and review of literature sources to identify potential individual case safety reports (ICSRs) and signal detection along with an initial evaluation of events of special interest. They also do Safety Evaluation and Risk Management (SERM) and provide aggregate reports for generics and established products and conduct ongoing Benefit Risk evaluation.

The Pharmacovigilance Agreements and Safety Clauses (PVASC) team is involved in reconciling/drafting PV agreements with Business Partners. They are also involved in Vendor oversight Management and provide Technical Associate support.

The Clinical Trial Transparency and Publications teams support global disclosure commitments and key publications activities. Pipeline Project management group creates plans for the Pipeline & in development projects and work at the Portfolio level to manage project timelines, budget & resources. They also support Quality, Bioethics and Policy (BEP) and Grants & Donations (G&D) for global needs.

The presence of these diverse R&D teams showcases GSK's commitment to quality, collaboration, and innovation in the pharmaceutical industry.





United As One for Patients to help create, improve and prolong lives

Merck Healthcare R&D India Hub: A Young & Vibrant team of Experts

The Merck Healthcare R&D India hub was established in 2020 as an Excellence Center. Ever since the organization has attained a series of milestones and evolved from being an Excellence Center to a Global Hub and continues to contribute to Merck Healthcare R&D's ambition of delivering the healthcare solutions of tomorrow that can help treat difficult ailments in patients around the world. Today, the R&D India hub comprises a team of talented professionals fostering a strong culture of collaboration, curiosity, and innovation, while delivering critical responsibilities in Merck's drug development journey.

Headquartered in Bengaluru, with offices in Mumbai and Hyderabad, R&D India Hub focuses on leveraging



GCC: Bengaluru



No. of Employees:
~500

the talent footprint and technological advances in India to enable the organization in its journey to accelerate innovation and bring more medicines to more patients faster. The hub's objective is to drive innovation across the scientific community by leveraging India's wealth of scientific talent and technological advances, to enhance healthcare solutions across the world. In the past one and a half years the organization has shaped up various functions critical to R&D. Now that the organization has established itself as a global hub, the focus primarily is on strengthening its expertise and core competencies in India and enhancing global collaboration and innovation.

Fostering Innovation through technology

The Hub extends its support to the global team in the disease areas, including oncology, fertility, endocrinology, neurology, immunology, and general medicines. The hub focuses on enabling and supporting the following functions, that are critical across R&D:

- Global Regulatory Affairs (GRA) harmonizes and centralizes regulatory execution, driving deliverables in strong collaboration with the global R&D functions and

"Our primary focus has been to build capabilities around electronics, life science and healthcare. We have an entire gamut of technological capabilities encompassing the creation of applications, marketing and sales initiatives, as well as ERP implementation and support."

Anuprita Bhattacharya
Head, Merck IT Centre, India

- other R&D hubs in healthcare. The team comprises License Management, Chemistry Manufacturing Controls (CMC), Labelling, Data Management, Data Analytics, Identification of Medicinal Products (IDMP), and Regulatory Operations.
- Global Patient Safety (GPS) monitors the safety of Merck's medicines throughout their use in healthcare practice. The team collaborates with the global R&D functions and plays a significant role in integrating deep knowledge of safety into early decision-making.
- Global Development Operations (GDO) in alignment with the global R&D functions deliver clinical study portfolio leveraging technology and digital innovations.
- Global Regulatory and Safety Writing Hub (GRSWH) team of medical writers focuses on bringing

- data to life in core decision-making, with a focus on consistently delivering or improving medicine.
- Statistical Programming (SP) team is responsible to provide statistical analysis results to answer the objectives of the clinical trials and/or any research questions by presenting collected data in the format of Tables, Listings, and Figures.
- Global Scientific Communication Content Hub (GSCCH) manages scientific exchange to enhance patient care by improving efficiency

- and ensuring quality and consistency. Strategy, Portfolio, External Innovation, Hubs (SPEIH) shape and drive the pipeline evolution, leveraging high-quality analytics, efficient project leadership, innovation, and global footprint.

The R&D India Hub strives to bring the best of global practices and local talent to enable its vision and enhance patient outcomes. The Hub empowers its employees with an innovation-friendly environment that encourages

their curiosity. The vibrant and young team of R&D India Hub joins around 64,500 curious minds from across the globe who are constantly working on innovative technologies to help drive sustainable human progress.

"We are evolving into a true global hub. One day we will see end-to-end functions being run from India"

Suneela Thatte
VP & Head, Healthcare R&D India at Merck.



Merck HC R&D Inauguration



HC R&D_TH



HC R&D Independence Day





Leveraging break-through science to better lives.

MSD: Innovation that gives hope to humanity.

MSD, known as Merck & Co., Inc., in the United States and Canada, is unified around its purpose - using the power of leading-edge science to save and improve lives around the world. For more than 130 years, the company has brought hope to humanity through the development of innovative medicine and vaccines. MSD aspires to be the premier research-intensive biopharmaceutical company in the world – and today, they stand

at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases. They foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities.

Strong presence, stronger performance.

MSD has a longstanding presence in India. The company delivers innovative healthcare solutions across multiple therapeutic areas including diabetes, oncology, vaccines, and critical care available in 80,000+ pharmacies through 2500+ distributors. Led by a strong team of 1500+ employees across India, MSD's mission is to serve more patients each day by bringing and improving access to innovative treatments that deliver better health outcomes. Through their operations in India, they create more than 4,200 jobs directly and indirectly across their operations in India including their Offshore Development Centers.

MSD has demonstrated a continued commitment to tackling some of the most pressing health issues of every generation, from smallpox, to measles, to HPV. With the rising disease burden of Cervical Cancer in India, the second most

common cancer among women, MSD is primed to support the Indian Government in protecting every woman through HPV vaccination and eliminating cervical cancer from the country.

In India. For India and the world.

MSD 'makes for India' in India and for the world. Nearly 85% of their products are manufactured locally. MSD also has 4 contract manufacturing sites in India, making India an important global supply hub for the company. India also continues to be one of the company's largest sourcing hubs for APIs for products manufactured all over the world.

Amidst the COVID-19 crisis in India in December 2021, MSD announced voluntary licensing agreements with 8 Indian manufacturers to accelerate and expand global access to Molnupiravir, an oral therapeutic treatment for COVID-19. The antiviral treatment was completely sourced, manufactured, and made in India, for India and was being exported to more than 100 low-and middle-income countries from India.

Dedicated Digital & Analytics Hub, Pune

In 2022, MSD set-up a dedicated Insights, Analytics & Data center in

Pune, India to use the power of data & analytics in improving patient and business outcomes worldwide. The hub provides near shore capabilities including driving personalized engagement, performing strategic forecasting, applying digital and web analytics, driving health equity work, optimizing investment, and providing market performance analysis to MSD's businesses in Asia-Pacific, Europe, and Africa. MSD has invested over \$16 Mn in setting up this pioneering center. The center is benefiting from the high-quality talent in India and has expanded its team nearly three-fold in just two years.

Supporting Start-ups in India.

MSD has made an investment in HealthQuad, India's leading healthcare venture capital fund, to help advance health equity. This investment will contribute to robust and sustainable healthcare ecosystem through innovative solutions in financial inclusion, patient engagement, and supply chain, in India and around the world. They have also partnered with 10+ new-age start-ups to ensure that they are consistently delivering better service to patients and doctors. One such example is MedGenome which has helped provide access to PDL1 testing for patients. Through this partnership, MSD has been able to screen ~700 patients annually.

MSD FOR THE COMMUNITY

MSD FOR MOTHERS is a global initiative which aims to create a world where no woman dies while giving life. Through this initiative, the company has helped more than 20 million women in nearly 64 global sites around the world have healthier pregnancies and safer childbirths, contributing to the global effort to end maternal mortality and morbidity. Applying MSD's business and scientific resources, they are collaborating across sectors to improve the health and well-being of

women during pregnancy, childbirth, and the months after.

Since 2013, MSD for Mothers has taken a comprehensive approach to advancing the quality of private maternity care in India to meet women's maternal health needs. So far, MSD for Mothers has reached 10 million women, trained 300,000 health providers, and strengthened more than 3,500 facilities in the country.

In India, they are partnering with Federation of Obstetric and Gynaecological Societies of India (FOGSI) to improve private providers adherence to WHO standards via the Manyata program. Currently there are over 135 Manyata registered maternity facilities in Jharkhand and around 2500 across the country, ensuring high-quality, safe, and respectful maternal care.

To address the challenge of lack of proper infrastructure – MSD has partnered with iKure, a population health management company that focuses on innovations for bridging that gap by delivering affordable, accessible & quality primary healthcare to underserved communities across India

beyond tier-I cities. iKure has been working to support the Government of Jharkhand on a Maternal Health Program in the Aspirational District of Khunti by providing localized solutions to solve the gap in ANC services to drive efficiency, consistency, and risk stratification of expectant women.

MSD SMILE ON WHEELS: In the company's efforts to improve access to quality primary healthcare services, they are mobilizing Mobile Medical Units across 9 aspirational districts in UP, Bihar, and Jharkhand, in partnership with Smile Foundation. The program aims to reduce out of pocket expenses by rendering outpatient services, improving health seeking behavior, increasing demand for quality health services, reducing the burden on Government health facilities, and ensuring safe motherhood of pregnant & lactating mothers.

"India possesses the ideal combination of talent, opportunity, and growth potential, making it a pivotal market for future growth."

Rehan A Khan
Managing Director, MSD India



Location: GCC: Insights, Analytics & Data Center, Pune

Employees: No. of Employees: ~300

Investment: >\$16mn



Developing in India for the world

Improving and extending people's lives

Novartis is a focused innovative medicines company, striving to reimagine medicine that will improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Their wide range of medicines reach more than 284 million people worldwide.

Partnering for India's health for over 75 years

Novartis has had a significant footprint in India since 1947, with

two legal entities namely Novartis Healthcare Private Limited and Novartis India Limited.

India is amongst a handful of countries in the world that have a broad Novartis footprint including Novartis Corporate Center which houses the Global Capability Center and R&D teams; and commercial operations.

Novartis Corporate Center is one of the important centers in the global organization, supporting their purpose of reimagining medicine. This center has the Global Capability Center with ~5400 employees. The center also serves as one of the key Global hubs for Development with ~2300 employees. Here scientists are providing support in the development of many chemical entities developed and commercialized by Novartis globally. These innovative medicines save millions of lives around the world.

Commercial operations has about 600 employees focusing on working towards improving access to their innovative portfolios for Cardio Renal Metabolics, Oncology and Spinal Muscular Atrophy.

Consistently been recognised as a Top Employer, Novartis in India is home to >13% of the company's global workforce.

"We were among the pioneers when we set up our GCC in Hyderabad nearly 15 years ago. Today, it is our largest Novartis Corporate Centre and one of the important centres in the global organisation that is fueling our next phase of growth."

Naveen Gullapalli
Global Head, Novartis Corporate Centres

Pioneering Excellence at the Novartis Corporate Centre

Novartis was among the pioneers when they setup a Global Capability Centre in Hyderabad nearly 15 years ago. Today, there are six such centres across the world, strategically spanning different time zones. It was recently renamed the Novartis Corporate Centre (NOCC), and stands proudly as the largest one. NOCC is fuelling the purpose of reimagining medicine.

The centre is key to Novartis' vision and provides high-quality support service across multiple functions and capabilities - Drug Development, Business Services, Data, Digital & IT, Manufacturing Supply and Quality, Procurement & Real Estate, Human Resources, Finance, Risk & Compliance, Legal,



GCC:
Hyderabad



No. of Employees:
~8,000



Investment:
\$400mn

Communications & Engagement. This hub is one of the very few GCCs who have gone beyond the conventional tech-heavy presence to diversify into other areas where the talent pool availability in India can be tapped to drive enterprise value at scale.

This centre houses over ~7700 associates with ~38% diversity and accounting to the cost of operations at ~USD 400 million.

Promoting Innovative Solutions: Novartis Global Development in India

The Development division is responsible for advancing Novartis' pipeline of investigational medicines, to bring transformative new treatment options to patients with serious diseases. It leads the clinical development of potential new medicines, running large clinical trials and generating evidence that turns molecules to medicines.

India serves as one of the key global hubs for development. Over two

decades of its presence in India; the company has evolved to be an integral part of the development journey of many breakthrough medicines in various therapeutic areas like cardiovascular, oncology, immunology, neurology, ophthalmology amongst others. The India centre also has the presence of all global functions including Global Clinical Operations, Technical R&D, Patient Safety and Pharmacovigilance, and Regulatory Affairs, to name a few.

Of the total ~12,000 Global Development employees, ~18% are based in India, playing an important role in supporting the company's long-term growth and delivering on its purpose to improve and extend people's lives.

For the last 12+ years, technical R&D within Development has been increasing its footprint in Genome Valley, Hyderabad and currently 350+ scientists including Masters, PhDs and post doctorates are contributing to the pharmaceutical development of

new chemical entities.

The Indian scientists are providing support in the development of many chemical entities developed and commercialized by Novartis globally. These innovative medicines save millions of lives around the world.

Contributing to Science, Returning to Society

At Novartis, the company uses science-based innovation to address some of society's most challenging healthcare issues. Building trust with society with responsibility is a key pillar of the Novartis corporate strategy. It defines their approach to managing their key Environment Sustainability Goals (ESG) and corporate responsibility topics and risks: being part of the solution on pricing and access, addressing global health challenges, being a responsible citizen, and holding themselves to high ethical standards. The company owns a long-standing commitment towards Zero Leprosy and Water Neutrality, amongst others.

Vas Narasimhan, CEO, Novartis, addressing India associates at NOCC



Associates exploring the divisional booths at the carnival



Ice breaker and engagement sessions for the associates at the carnival



Cross divisional engagements between site initiative groups and associates





A Century of Innovation...

A Century of Care!

Novo Nordisk is over a hundred-year-old healthcare company that has constantly worked for the benefit of people living with serious chronic diseases all around the world.

From the breakthrough commercialization of insulin - a game-changer in diabetes care - way back in 1923 to creating new hope for people with haemophilia in 1996, to pioneering advances in growth hormone therapeutics more than 30 years ago, the company has always striven to focus on the unmet needs of patients.

The company continues to build on its strong legacy even today. Significant breakthroughs in regenerative medicine, such as stem cell therapy, give hope to the ultimate goal of finding a cure

for debilitating chronic diseases such as Type 1 diabetes and Haemophilia. Riding on unparalleled research and cutting-edge technology, the company is pioneering therapies to reduce the number of insulin injections required by individuals, prevent low blood glucose (hypoglycaemia) episodes, redefine protein engineering, and tackle endocrine disorders, to name a few.

Continuing the tradition of trust.

In India, the company has continued these endeavours. Novo Nordisk set up a base in Bengaluru in 1992 and has become the 4th largest and one of the fastest-growing pharmaceutical MNCs in India today. At present, in India, Novo Nordisk is taking up phase 2-4 clinical trials in all major disease areas with over 3000

patients enrolled. With an impressive 37 trials ongoing, in multiple therapy areas, India contributes to 7-8% of the global patient pool within Novo Nordisk.

In 2007, the company started the Novo Nordisk Global Business Services, as a transactional service centre for finance, patents, and data management. Over the years, NN GBS has evolved and

“Our GBS serves as an integrated extension to our headquarters in Denmark, and Bengaluru has emerged as a strategic location for highly skilled talent, tech innovation, and a robust startup ecosystem.”

John C Dawber
Corporate VP & MD - Global Business Services, Novo Nordisk



Microsoft Teams

grown, adding core services around commercial affairs, supply chain, quality, development etc. It offers an abundant talent pool across functional areas and has provided significant cost savings to the global organization over time. The hub employs over 4000 full-time employees, supporting global business needs. This includes doctors, pharmacists, analysts, statisticians, medical writers, commercial experts, IT specialists and more. All working together in a perfect, collaborative way, such that their expertise can be leveraged to place the centre as a strategic partner to the parent company and acting as the destination for transformation and digital innovation.

The centre offers solutions in the following areas:

- Finance
 - Medical Affairs
 - Safety Operations
 - Regulatory Affairs
 - Clinical Reporting
 - Biostatistics
 - Drug Development
 - Data Management
 - Legal & Patents
 - Commercial Affairs
 - People Operations
 - Quality
 - DD&IT
 - Supply Chain
- ...and taking it further.

Novo Nordisk continuously engages with external scientific congresses and societies – contributing through thought leadership, work streams, and paper presentations on solutions. These include PHUSE (Global Healthcare Data Science Community), IASCT (Indian Association for Statistics in Clinical Trials), SCDM (Society for Clinical Data Management (SCDM), etc. The company has also signed MoUs with MAHE, Manipal and IIIT Bangalore PSG Tech Coimbatore and other universities in South India, to offer their students Internship opportunities within their company.

Local Investigators Meeting



 GCC: Bengaluru



No. of Employees:
>4000



Promoting Innovation; Perfecting Healthcare.

Beacon of scientific excellence.

In the realm of pharmaceutical innovation, Pfizer India stands tall as a beacon of excellence, harnessing the nation's rich scientific heritage and academic prowess to drive global research and development efforts. Nestled within the vibrant scientific ecosystem of India, Pfizer's Global Drug Development Centre in Chennai emerges as a powerhouse of innovation, propelling the company's quest for groundbreaking medical solutions.

Research, development and the drive to make a difference.

At the heart of Pfizer's global Research and Development network, the Chennai facility epitomizes a commitment to excellence in pharmaceutical science. Boasting state-of-the-art infrastructure and a team of dedicated experts, this center serves as a crucible for the

development of complex sterile injectable formulations and device combination products. With a keen focus on small molecules, innovative formulations, and active pharmaceutical ingredients (APIs), Pfizer Chennai spearheads transformative research tailored for global markets.

Central to Pfizer's success in Chennai are its exceptional teams, epitomizing the pinnacle of scientific excellence. The Pharmaceutical Sciences and Sterile Manufacturing (PSSM) team, comprising over 80 scientists and technicians, operates at the forefront of pharmaceutical innovation, providing multifaceted support across 30 capabilities and over 10 products. As the team undergoes expansion, with a surge in headcount and capabilities, it heralds a new era of innovation in drug development, poised to redefine healthcare paradigms by 2025.

Additionally, the Global Technology and Engineering (GT&E) team, comprising 89 professionals, serves as the backbone of Pfizer's global operations, delivering unparalleled support across 19+ capability domains. With ambitious expansion plans on the horizon, including significant investments in equipment advancement and infrastructure expansion, the GT&E team solidifies Pfizer's position as a trailblazer in pharmaceutical research and development.

Fostering world-class education.

Beyond the confines of its laboratories, Pfizer India fosters symbiotic partnerships with esteemed academic institutions, including the prestigious Indian Institutes of Technology (IITs). Through strategic collaborations and MoUs, Pfizer Chennai pioneers initiatives aimed at nurturing talent, fostering innovation, and advancing pharmaceutical education. From curriculum development to student sponsorships, Pfizer's collaboration with IIT-Madras exemplifies a synergistic blend of academia and industry, propelling scientific discourse and nurturing the next generation of pharmaceutical pioneers.

Empowering employees.

Moreover, Pfizer's unwavering commitment to employee development underscores its status as an employer of choice in the pharmaceutical landscape. By facilitating upskilling initiatives and encouraging employees to pursue advanced degrees and short-term courses at IIT-Madras, Pfizer fosters a culture of continuous learning and innovation, ensuring a steady influx of talent and expertise into its ranks.

Endorsing Innovation.

In their strife to serve the communities in which they live and work, and strengthen academia in the country, Pfizer also has

agreements with premier universities and institutes to partner with them on curriculum development, fellowships, adjunct faculty positions, trainings, internships, and campus placements.

Recently, Pfizer collaborated with the National Institute of Pharmaceutical Education & Research (NIPER), Ahmedabad to give an added boost to healthcare start-ups in India, helping them turn their ideas into market-ready solutions. This initiative, called the INDovation programme, will incubate six healthcare startups with an investment of ₹25 lakh each. Following a cohort-based approach, these start-ups will be selected from across the country for a one-year accelerator programme.

Pfizer will be looking for innovations at technology readiness level (TRL) 3 or higher in the areas of deep tech and artificial intelligence for predictive analysis, point-of-care testing, software-as-a-service, informatics and wearables, and track and trace solutions. In addition to the ₹25 lakh investment, each of these startups will receive incubation support in the areas of product development, regulatory pathway, pre-clinical testing, tech

transfer support through the NIPER ecosystem, and a real-world clinical fitment check.

The initiative is supported by the Department of Pharmaceuticals and Niti Aayog, and anchored by Social Alpha.



 GCC: Chennai

 No. of Employees: ~1000



FORMULATION DEVELOPMENT LAB
ONCOLOGY/POTENT MOLECULES

ISOLATOR



FLOW REACTOR



POTENTIOMETER



A healthier future. It's what drives us to innovate

To continuously advance science and ensure everyone has access to the healthcare they need today and for generations to come. Creating a world where we all have more time with the people we love.

That's what makes us Roche.

Roche at a glance: Doing now What Patients Need Next

For over 125 years, we have taken on some of the most complex challenges in healthcare. Listening and responding to the ever-changing needs of people around the world. Today, Roche has grown into one of the world's largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.

We are driven by science and our ambition of delivering better outcomes, for more patients faster. We are committed to facilitating rapid, broad, sustainable access to our innovations,

on a global scale. We strive towards converting today's knowledge into tomorrow's therapies.

- No.1 R&D investor in healthcare and the third highest across all industries. R&D investments of CHF 14.1 billion in 2022
- 33 R&D and 20 manufacturing sites worldwide
- 89 New Molecular Entities in clinical development
- 14.2 million patients treated with our medicines
- 29 billion tests conducted with Roche Diagnostics products
- 32 Roche medicines on the WHO model list of essential medicines

Roche in India: partnering India in its healthcare journey since 1950s

- For more than 60 years, Roche has been committed to making a difference to the lives of people in India. From being a key distribution market for the iconic cough syrup Sirolin, to manufacturing vitamins in the late 1950s, to the introduction of advanced targeted and immunotherapy medicines for treating different forms of cancer and foraging into newer therapy areas of Ophthalmology and Neuroscience; we have endeavored to bring the most innovative and path-breaking drugs to Indian patients.

In India, our portfolio of power brands across therapy areas

- **Oncology:** Alecensa, Gazyva, Kadcyca, Perjeta, PHESGO, Tecentriq, Polivy*
 - **Hematology (Haemophilia):** Hemlibra
 - **Neuroscience (Spinal Muscular Atrophy):** Evrysdi,
 - **Neuroscience (Multiple Sclerosis):** Ocrevus*
 - **Ophthalmology:** Vabysmo*
- * Innovations launched in India in 2023/24

- **'The Blue Tree' patient support program** to improve affordability and access has supported 19000+ until 2023. First company to launch a mobile-based application to provide comprehensive patient support services. To know more about the program, call on the toll-free number: 1800-266-3366: Oncology & Rare disease | 1800-202-8485: Ophthalmology and Multiple Sclerosis
- **State-of-the-art and industry felicitated supply chain:** Roche's product serialization and 'Track and Trace' systems ensures product quality, end-to-end traceability of our products, inventory and sales data on a real time basis and helps us address the issue of counterfeits.



GCC:
Innovation Centres
in Chennai, Pune

Investments in India:

Roche is harnessing India's rich engineering talent and robust technology ecosystem to forge ahead in the digital landscape, crafting innovative solutions that resonate on a global scale. As we delve into this transformative journey, India emerges as a pivotal investment market for Roche, underscoring our steadfast dedication to tackling unmet healthcare needs and spearheading impactful change within the industry.

- Roche Information Solutions (RIS) at Pune: India serves as a key site for RIS globally. RIS has emerged as Roche's "healthcare digital Centre of Excellence". The site is 100% aligned with Roche's new agile ways of working in all areas - business, group functions, and global functions. The Pune Digital CoE will be Roche's largest footprint in India in 2024. The Digital CoE has been playing a pivotal role in

integrating data across the patient healthcare journey. The advanced data analytics tools are simplifying decision-making for clinicians and patients thus supporting the larger objective of providing Personalized Healthcare and Decision-making capabilities.

- Offshore Development Center (ODC) in Chennai, in partnership with ZS Associates: The Centre consolidates existing data and analytics business operations services of all Roche Pharma affiliates at one place. This dedicated Roche ZS Associates ODC named YODAc (Your One stop shop for Data & Analytics Center) brings together many capabilities such as business data operations, data quality management, global analytical product support and other ad hoc services.
- Roche Services and Solutions India: Roche Services and Solutions (RSS)

India will be at the center of the Global Capability Center revolution in India. The Centre adds to expertise around the technological advancements happening in the healthcare space through utilization of AI/ML concepts contributing towards significant improvement in the lives of patients. As an analytics and technology center of excellence, the objective is to look beyond the obvious and provide actionable insights and solutions through data and technology to various business functions of Roche.

"India as a geography is the right place and it's the right time. In just two years of formation of Roche Information Solution India, members from the site at Pune have been part of global teams that have filed five patents so far."

Raja Jamalamadaka
MD, Roche Information Solutions India

Roche Information Solutions, India Office building



Roche Digital Day



Coffee Sessions



Townhall



Office Environment



Roche Global Creator event



A formal discussion of ideas and prototyping



Roche Global Creator event speaker sessions



A regular workday in the office at the innovation center



The innovation center office



A discussion around the status of multiple innovative solutions is underway



A relaxed collab space to nurture new ideas



An casual stand up meeting



sanofi

Innovation and expertise. From India to the world!

Heritage of Healthcare!

Established in 1973, Sanofi SA is a French multinational pharmaceutical company, that was formed by the amalgamation of diverse companies sharing a rich history in healthcare innovation, dating back to the 18th century. With a strong presence in 90 countries and with over 91,000

employees, the company offers innovative solutions in preventive healthcare and covers therapeutic areas of diabetology, immunology, neurology, dermatology, respiratory, and gastroenterology. Sanofi's pioneering work in the rare diseases space and its advocacy in building strong partnerships with rare disease community, is well acclaimed.

of science to improve peoples' lives. This MSAT- Manufacturing Sciences, Analytics & Technology centre has developed expertise in various dosage forms such as tablets, capsules, syrups, suspensions, nano formulations, etc., that the company manufactures.

R&D activities and ongoing research at this Centre of Excellence encompasses new product development, lifecycle management of established products, new dosage forms and formulations for easy administration, support R&D projects, and delivers technology transfer to commercial sites, troubleshooting for industrial sites, product harmonization, process improvements & robustness. It also covers support for compliance activities.

In the last half century, Sanofi has grown into one of the world's leading healthcare companies. It holds the distinction of being the first worldwide supplier of the injectable polio vaccine! This was followed by influenza, meningitis, and rabies vaccines, all firsts, too. Today, a whopping 500 million + people worldwide are protected by Sanofi vaccines.

In India since 1956, the company has aimed to break the barriers of existing lines of treatment and develop newer, more effective ways to improve healthcare in the country.

Sanofi has set up a hub in Hyderabad in 2019. It is a captive organization supporting medical, digital, commercial amongst other functions. Current key capabilities span scientific writing, data analytics, biostatistics and statistical programming. The hub employs 800 people with plans of further expansion.

R&D: Leading the way to better health solutions.

Sanofi's DSIR approved R&D centre in Goa, has, over the last 15 years, built in scientific rigor to develop innovative products and technologies in their quest to chase the miracles

Tie-ups that build a community.

As part of their mission to facilitate and engage with the local community,



GCC: Goa



No. of Employees:
~70



GCC: Hyderabad



No. of Employees:
~800

for knowledge sharing and building scientific expertise and industry academia collaboration, the company has tied up with Goa College of Pharmacy, Panaji and Don Bosco College of Engineering, Margao, both institutions in Goa. They have

also collaborated with NIPER, Mohali, Punjab. The company also offers Industrial exposure to several Pharmacy College students from Goa, Maharashtra, Karnataka, Tamil Nadu, and several other States.

R&D Centre



People working in R&D Centre



Labs



About OPPI

The Organisation of Pharmaceutical Producers of India (OPPI) established in 1965, represents the research-based global pharmaceutical companies in India. OPPI has been an integral part of the healthcare journey of the country. We remain committed to supporting the nation's healthcare objectives, putting patients at the core of all decision making and collaborating with all stakeholders to find sustainable solutions to realize the collective vision of Health for All.

Our member companies have been serving the country's healthcare ecosystem since pre-independence and continue to remain committed to patient safety and providing quality care in the future as well. As an association, our advocacy decisions, patient commitment and work are always keeping the country first and we embody the spirit of working for 'Bharat Ke Liye'; driven with innovation to find solutions for unmet medical needs, collaboration with government stakeholders, and co-creation with partners coming together to address the nation's healthcare challenges. We are committed to the Hon'ble Prime Minister Shri Narendra Modi-ji's clarion call of 'Jai Vigyan and Jai Anusandhan'.

About Bharat Ke Liye

Bharat Ke Liye captures the essence of OPPI's commitment towards India, one that's backed by innovative solutions with a mission to improve the country's healthcare infrastructure. Along with our member companies, we have been a strong partner to the nation since pre-independence. With a strong Indian ethos and a deep understanding of the country's complex fabric, we have been investing in India to build a healthier and stronger country.

As we move towards India@100, we will continue to partner with the Government to advance its vision of Healthcare for All, investing in building India's capability to solve the health challenges of its people & the world at large. It's important now more than ever before to CONVERGE, COLLABORATE, and CO-CREATE with the Government and other stakeholders in India.

We are #BharatKeliye

We were there

Since pre-independence, we've partnered with India to eradicate many diseases, address many epidemics, and solve health problems; together.

We are there

We've been collaborating for critical support during the pandemic, co-creating with the government to strengthen our healthcare ecosystem, converging our knowledge, and leveraging technology to innovate for unmet medical needs, all in an effort to improve the quality of care & access to healthcare.

We will be there

As we work towards India@100, we pledge to keep investing in the future of the nation, pushing boundaries of innovation, research, and development, to make every Indian healthy, prosperous, and resilient.

Partnering India on its mission to progress, amplifying our Hon'ble PM Shri Narendra Modiji's clarion call of **Jai Vigyan, Jai Anusandhan!**

Editor - *Asawari Sathaye, Director Communications and Patient Advocacy, OPPI*
Content Coordinator - *Clara Rodricks, Executive Assistant, OPPI*

We gratefully acknowledge the support received from our members companies.

The contents of Global Capabilities Centres Report are the copyright property of Organisation of Pharmaceutical Producers of India. Content may not be reproduced in any form without prior written permission.

Connect with us on:



@OPPIIndia



OPPI India



Organisation of Pharmaceutical Producers of India (OPPI)



OPPI



www.indiaoppi.com



events@indiaoppi.com



Organisation of Pharmaceutical Producers of India

Registered Office: 1620, C Wing, One BKC, Bandra Kurla Complex, Bandra East, Mumbai-400051, India.

Delhi Office: S6, Vatika Business Centre, Thapar House, Third floor, Gate #1, 124, Janpath, New Delhi 110001, India.

Novo Nordisk Driving Innovation, Access to Care and Sustainability

- Bharat Ke Liye

INNOVATION



>3,000*

patients are participating
in phase 2-4 clinical trials



37* trials

ongoing in multiple
therapy areas



contributing to **8%***
of the global patient pool
within Novo Nordisk

ACCESS TO CARE



>2,20,795*
patients reached
via



CHANGING DIABETES' BAROMETER

changing
diabetes®
in children



An initiative by Changing Diabetes® in Children

and Affordability programmes

SUSTAINABILITY



>5600*

employees across 14 functions*
with global process ownership.



LEED Platinum
Certified Building



The Best Place
to Work in India

*Data on file as of April 2024

